ESMO 2023 | Dr. Oliver Sartor: Lu-PSMA therapy could benefit mCRPC patients
Prostate cancer remains a significant health concern, especially in its metastatic castration-resistant form, which poses a formidable challenge for both patients and healthcare providers. Despite ongoing advancements in treatment options, the battle against this deadly disease continues. However, recent research has illuminated a ray of hope through the use of PSMA Lutetium therapy. In this article, we delve into the insights presented by Dr. Oliver Sartor at ESMO 2023 regarding the safety, efficacy, and potential benefits of PSMA Lutetium therapy in the treatment of metastatic castration-resistant prostate cancer.